Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952602 | 0.90 | NQO1 (0.37) | BRD4NQO1SMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL21791996 | 0.86 | LMNA (0.34) | BRD4LMNANQO1CYP26A1SMN1; SMN2 | |
| SCHEMBL18322046 | 0.80 | NQO1 (0.48) | NQO1 | |
| SCHEMBL23634123 | 0.77 | CA1 (0.38) | SMN1; SMN2MAPT | |
| SCHEMBL28620218 | 0.71 | CYP26A1 (0.43) | BRD4CYP26A1MAPTCYP24A1DRD2 | |
| SCHEMBL18322178 | 0.70 | BRD4 (0.38) | BRD4CYP26A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18322087 | 0.70 | NQO1 (0.49) | NQO1 | |
| SCHEMBL18321982 | 0.69 | FFAR1 (0.41) | BRD4CYP26A1CYP24A1 | |
| SCHEMBL20241215 | 0.69 | BRD4 (0.43) | BRD4CYP26A1MAPTPDE1BL3MBTL1 | |
| SCHEMBL20952649 | 0.69 | CYP26A1 (0.37) | BRD4CYP26A1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | BRD4 509/4885LMNA 2478/4885NQO1 3/4885 |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | BRD4 509/4885LMNA 2478/4885NQO1 3/4885 |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | BRD4 547/4885LMNA 2169/4885NQO1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.